The fourth annual European Business Development Conference was held in Munich attracting more than 100 CEOs and senior executives from US and European (bio)pharmaceutical, private equity, and venture capital companies.
The Federal Economics Minister, Rainer Brüderle, invited a member of the board of BIO Deutschland, Jan Schmidt-Brand (CEO of Heidelberg Pharma AG), to accompany him on his trip to Israel on 13 and 14 June.
The Act on Medication for Compassionate Use and the topic of Advanced Therapy Medicinal Products (ATMP) were the main subjects discussed at a meeting of BIO Deutschland’s Working Group on Regulatory Matters in Munich on 8 June.
“The venture capital used to fund innovations is increasingly withdrawing from Germany,” according to Olaf Wilhelm, a member of the board of BIO Deutschland, speaking at the trade press conference at Europe’s largest biotechnology trade fair, Biotechnica, in Düsseldorf on 17 June.
China is now one of the most dynamic economies in the world – and is also very active in the field of biotechnology. A delegation from Germany had the chance to gain an insight into the current state of affairs in Chinese biotechnology at the fourth BioChina in Jinan (Shandong Province).
Statement by BIO Deutschland on the Review of the Law on Genetic Engineering by the Federal Constitutional Court
At the start of the review of the German Law on Genetic Engineering by the Federal Constitutional Court on 23 June, BIO Deutschland called for a radical rethinking of the approach to plant biotechnology.
At the latest Annual General Meeting of the European biotech association, EuropaBio, which was held in Brussels on 23 and 24 June, Peter Heinrich, Chairman of the Board of BIO Deutschland, was elected to the board.
BIO Deutschland made use of the opportunity provided by the discussion organised by the Small and Medium Entrepreneurs Union of the European People’s Party (SME Union) and the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) with members of the EU Parliament to point out the funding situation faced by innovative biotech SMEs.